Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tofacitinib etocomil - Minghui Pharmaceutical

Next Previous
Drug Profile

Tofacitinib etocomil - Minghui Pharmaceutical

Alternative Names: LBP-ShC4; MH 004

Latest Information Update: 19 Aug 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Minghui Pharmaceutical (Shanghai)
  • Developer Minghui Pharmaceutical (Shanghai); Shanghai Fosun Pharmaceutical
  • Class Anti-inflammatories; Antirheumatics; Skin disorder therapies
  • Mechanism of Action Janus kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Atopic dermatitis; Vitiligo
  • Preclinical Alopecia
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 04 Aug 2026 Phase-III clinical trials in Vitiligo (In adolescents, In the elderly, In adults, Treatment experienced) in China (Topical) (NCT07682506)
  • 13 Jul 2026 Discontinued - Preclinical for Rheumatoid arthritis in China (Topical) (Shanghai Fosun Pharmaceutical pipeline, July 2026)
  • 13 Jul 2026 Preclinical trials in Alopecia in China (Topical), prior to July 2026 (Shanghai Fosun Pharmaceutical pipeline, July 2026)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top